No Priors: Artificial Intelligence | Technology | Startups Chai-2: The AI Model Accelerating Drug Discovery with Chai Discovery Co-Founders Jack Dent and Joshua Meier
77 snips
Jul 3, 2025 
Jack Dent and Joshua Meier, co-founders of Chai Discovery, share their groundbreaking work on the Chai-2 model, revolutionizing antibody design with a remarkable 20% success rate. They discuss how AI can optimize complex molecular properties, reshaping the landscape of drug discovery. The duo emphasizes the importance of structure prediction and offers insights into how biotech professionals can leverage this innovative technology. Tune in to hear their vision for the future of drug development and the skills bioscientists should embrace to thrive in this evolving field.
AI Snips
Chapters
Transcript
Episode notes
Chai-2's Breakthrough Antibody Design
- Chai-2 can design antibodies with a 20% success rate in binding targets, a 100-fold improvement over prior computational methods.
- This breakthrough promises faster and more efficient drug discovery, unlocking targets previously inaccessible to traditional methods.
Chai-2's Robust Generalization
- Benchmarking Chai-2 on 50 diverse targets confirmed its generalizability beyond training data.
- The model's ability to work on held-out, dissimilar protein sequences shows it learns fundamental molecular interaction principles.
Atomic-Level Molecular Design
- Chai-2 combines protein folding and generative modeling to design molecules atom-by-atom in 3D space.
- This atomic-level approach enables precise design of antibody keys that fit specific protein lock targets.